Brightstar Therapeutics, a Lexington, KY-based biotechnology company focused on providing treatment options for corneal and ocular surface diseases, raised an undisclosed amount in Series A funding.
The round was led by Saving Sight. Backers included Miracles in Sight, University of Minnesota Discovery Capital and VisionFirst Indiana Lions Eye Bank.
Led by CEO Rajan Shukla, and Rusty Kelly, Chief Operating Officer, Brightstar Therapeutics is a biotechnology company focused on providing innovative treatment options that improve clinical outcomes and quality of life for people living with corneal and ocular surface diseases. It offers a long-term solution for persistent epithelial defects, and partial limbal stem cell deficiency through its advanced corneal allograft, BrightMEM. The allograft encourages durable regeneration of the corneal epithelium, while providing protection for the underlying stromal tissue.
The company intends to use the funds to accelerate the launch of its approach to treating persistent epithelial defects and limbal stem cell deficiency with BrightMEM.
FinSMEs
21/04/2023